is dulaglutide a glp 1 Lilly's Easy-to Use Once-Weekly GLP-1 Agonist Trulicity Approved in Europe The Multifaceted Nature of GLP-1:

The medication binds to both receptor types with high affinity, creating a combined effect that exceeds single-receptor targeting approaches

Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1

Other considerations include hypoglycemia (most common concern), possible local tissue effects at injection sites, unknown long-term consequences of repeated local IGF-1 surges, and potential for organ growth with chronic use near specific organs

Importantly, GLP-1 RAs should be prescribed and managed by clinicians experienced in pediatric obesity (e.g., pediatric endocrinologists or obesity specialists) because of dosing complexities and the need for growth monitoring

Injection burden Can mix into one syringe or use two Best for Asymmetric dosing or staggered cycling Cycle driver Compound-specific titration CJC-1295 (no DAC) Loading 100 mcg Frequency Once daily Maintenance 200-300 mcg Route SubQ Ipamorelin Loading 100 mcg Frequency Once daily Maintenance 200-300 mcg Route SubQ Weekly Schedule Example Monday CJC-1295 200 mcg + Ipamorelin 200 mcg Tuesday CJC-1295 200 mcg + Ipamorelin 200 mcg Wednesday CJC-1295 200 mcg + Ipamorelin 200 mcg Thursday CJC-1295 200 mcg + Ipamorelin 200 mcg Friday CJC-1295 200 mcg + Ipamorelin 200 mcg Saturday CJC-1295 200 mcg + Ipamorelin 200 mcg Sunday CJC-1295 200 mcg + Ipamorelin 200 mcg When mixing both peptides into a single syringe, draw each peptide separately and combine in the syringe